In This Section

Program

Please Note: All session times for the AACR Virtual Meeting: COVID-19 and Cancer are U.S. Eastern Daylight Time (EDT).

Monday, July 20, 2020

Tuesday, July 21, 2020

Wednesday, July 22, 2020

Monday, July 20, 2020

Welcome and Opening Keynote Address
10-10:35 a.m.

Welcome
Antoni Ribas, University of California, Los Angeles, California

Welcome and Introduction of Keynote Speaker
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Keynote Address:
Coronavirus infections: More than just the common cold
Anthony Fauci, National Institute of Allergy and Infectious Diseases (NIAID), Rockville, Maryland

Break
10:35-10:50 a.m.
Symposium 1: Intersection of the Biology of SARS-CoV-2 and Cancer
10:50 a.m.-12:50 p.m.

Introduction
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

The crosstalk between cellular transformation and the response to SARS-CoV-2 infection
Benjamin tenOever, Icahn School of Medicine at Mount Sinai, New York, New York

Therapeutic targeting of TMPRSS2 and ACE2 as a potential strategy to combat COVID-19*
Irfan A. Asangani, University of Pennsylvania, Philadelphia, Pennsylvania

Optimizing treatment for COVID-19 using computational modelling: Implications for cancer patients*
Lance L. Munn, Harvard Medical School, Boston, Massachusetts

A prediction of prostate cancer deaths spiking by SARS-CoV-2 infection*
Alakesh Bera, Uniformed Services University, Bethesda, Maryland

Systems approaches reveal shared pathways affected in SARS-CoV-2 infection and cancer
Nevan Krogan, University of California, San Francisco, California

Closing Remarks / Discussion
David A. Tuveson

Symposium 2: Effects of Cancer Immunotherapies on Patients with COVID-19 (with and without Cancer)
10:50 a.m.-12:50 p.m.

Introduction
Elizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland

COVID-19 in patients with lung cancers in New York City
Jia Luo, Memorial Sloan Kettering Cancer Center, New York, New York

Clinical characteristics and outcomes of Coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)*
Aljosja Rogiers, Melanoma Institute Australia, Sydney, NSW, Australia

COVID-19 treatment candidate hydroxychloroquine impairs tumor response to anti-PD1*
Simon Wabitsch, National Cancer Institute, Bethesda, Maryland

SARS-CoV-2 induces inflammatory cytokine release, which may be exacerbated by immune checkpoint blockade*
Layne Weatherford, University of Cincinnati, Cincinnati, Ohio

COVID-19 and cancer: A new perspective on cancer care in the era of immunotherapy
Leora Horn, Vanderbilt Ingram Cancer Center, Nashville, Tennessee

Closing Remarks / Discussion
Elizabeth M. Jaffee

Forum 1: Regulatory and Operational Implications of Cancer Clinical Trial Changes During COVID-19
1:05-2:05 p.m.
Moderator: Keith T. Flaherty, Massachusetts General Hospital Boston, Massachusetts

José Baselga, AstraZeneca, Gaithersburg, Maryland
James Doroshow, National Cancer Institute, Bethesda, Maryland
Kristen M. Hege, Bristol-Myers Squibb, San Francisco, California
Paul G. Kluetz, U.S. Food and Drug Administration, Silver Spring, Maryland
Patricia M. LoRusso, Yale University School of Medicine, New Haven, Connecticut
Caroline Robert, INSERM U981 (Gustave Roussy), Villejuif, France

Forum 2: Telehealth
1:05-2:05 p.m.
Moderator: Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

Michael Businelle, Stephenson Cancer Center, Oklahoma City, Oklahoma
Greg Garber, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Jennifer L. Malin, UnitedHealth, Minneapolis, Minnesota
Ana Maria Lopez, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Paul Waller, Patient Advocate
Anna N. A. Tosteson, Norris Cotton Cancer Center, Lebanon, New Hampshire

Break
2:05-2:20 p.m.
Symposium 3: COVID-19 Vaccine Development
2:20-4:20 p.m.

Introduction
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

Rapid SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness
Kizzmekia S. Corbett, National Institutes of Allergy and Infectious Diseases (NIAID), Bethesda Maryland

Pan-HLA prediction of SARS-CoV-2 epitopes*
Katie M. Campbell, University of California, Los Angeles, California

Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes*
Asaf Poran, BioNTech US, Cambridge, Massachusetts

A computational approach to identify a possible SARS-CoV-2 vaccine from receptor binding domain peptide sequence on spike glycoproteins*
Majid Al-Zahrani, King Abdulaziz University, Jeddah, Saudi Arabia

Synthetic DNA for EID outbreaks including  SARS-CoV2
David Weiner, The Wistar Institute, Philadelphia, Pennsylvania

Closing Remarks / Discussion
E. John Wherry

Symposium 4: Cancer Drug Repurposing to Treat COVID-19
2:20-4:35 p.m.

Introduction
Keith T. Flaherty, Massachusetts General Hospital, Boston, Massachusetts

Title to be announced
Charles G. Drake, New York-Presbyterian/Columbia University Medical Center, New York, New York

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalized patients: A case series*
Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Treatment with Tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection*
Alexandra Cabanov, University of Chicago, Chicago, Illinois

A phase II trial to promote recovery from COVID-19 with endocrine therapy
Catherine H. Marshall, Johns Hopkins University School of Medicine, Baltimore, Maryland

Title to be announced
Louis M. Staudt, National Cancer Institute, Bethesda, Maryland

Closing Remarks / Discussion
Keith T. Flaherty

Tuesday, July 21, 2020

Keynote Address
10-10:35 a.m.

Introduction
Antoni Ribas, University of California, Los Angeles, California

Keynote Address:
Flexibility to sustain solidity: Addressing new vulnerabilities in cancer at the time of COVID-19
Solange Peters, CHU Vaudois, Lausanne, Switzerland

Symposium 5: Cancer Pathway Biologies Intersecting with COVID-19
10:50 a.m.-12:50 p.m.

Introduction
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York

Leveraging new insights from cancer drug discovery to target viral host factors
Kevan Shokat, University of California, San Francisco, California

Profound CD8 T cell responses towards SARS-CoV-2 OFR1ab in COVID-19 patients*
Anastasia Gangaev, Netherlands Cancer Institute, Amsterdam, The Netherlands

COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis*
Garth W. Strohbehn, University of Chicago, Chicago, Illinois

Preserving innate memory to overcome SARS-CoV-2 infection through the mevalonate pathway*
Juan Luis Gomez Marti, University of Pittsburgh, Pittsburgh, Pennsylvania

Treatment of COVID-19 pulmonary failure by targeting BTK
Steven P. Treon, Dana-Farber Cancer Institute, Boston, Massachusetts

Closing Remarks / Discussion
Dafna Bar-Sagi

Symposium 6: Continuity of Cancer Care
10:50 a.m.-12:50 p.m.

Introduction
Gary K. Schwartz, Columbia University, New York , New York

How a crisis informs management: Lessons about biology and social support
Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Changes implemented by U.S. oncology practices in response to COVID-19 pandemic: Initial report from the ASCO Registry on COVID-19 and cancer*
Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, Virginia

Cancer care telehealth utilization rates and provider attitudes in the wake of the novel Coronavirus pandemic: The Kaiser Permanente Northern California Experience*
Elad Neeman, San Francisco Medical Center, Kaiser Permanente Northern California, San Francisco, California

Continuing cancer care through a coordinated disease outbreak response system
Lim Soon Thye, National Cancer Center, Singapore

Closing Remarks / Discussion
Gary K. Schwartz

Forum 3: How Will We Bring Patients Back to the Clinic?
1:05-2:05 p.m.
Moderator: Nancy E. Davidson, Fred Hutchinson Cancer Research Center, Seattle, Washington

Howard A. Burris, Sarah Cannon Cancer Center, Nashville, Tennessee
Lisa M. DeAngelis, Memorial Sloan Kettering Cancer Center, New York, New York
Catherine Liu, Fred Hutchinson Cancer Research Center, Seattle, Washington
Patricia Spears, University of North Carolina, Chapel Hill, North Carolina
Josep Tabernero, Vall d’Hebron University Hospital (VHIR), Barcelona, Spain

Forum 4: How Cancer Researchers Are Applying Their Talents to COVID-19 Issues
1:05-2:05 p.m.
Moderator: Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York

Anna D. Barker, The Ellison Institute of USC, Los Angeles, California
Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Thomas J. Lynch, Fred Hutchinson Cancer Research Center, Seattle, Washington
Shiva Malek, Genentech, Inc., South San Francisco, California
J.T. Poirier, Perlmutter Cancer Center, NYU Langone Health, New York, New York

Break
2:05-2:20 p.m.
Symposium 7: Effects of COVID-19 on Cancer Survivorship: Impact on Cancer Patients and Professionals
2:20-4:20 p.m.

Introduction
Marina Garassino, Fondazione IRCCS Instituto Nazionale dei Tumori, Milano, Italy

COVID-19 pandemic and its effect on the psychological status of cancer patients and oncologists
Gabriella Pravettoni, University of Milan, Milan, Italy

Examining COVID-19 preventive behaviors among cancer survivors in the United States: An analysis of the COVID-19 Impact Survey*
Jessica Y. Islam, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Patient reported outcomes of breast cancer patients during the COVID-19 outbreak in the epicenter of China: A cross sectional survey study*
Juanjuan Li, Renmin Hospital of Wuhan University, Wuhan, China

Scientia Potentia Est: How the Italian world of oncology changes in the COVID19 pandemic*
Rossana Berardi, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy

Impact of COVID-19 related psychosocial distress on health-related quality of life in rural cancer survivors*
Scherezade K. Mama, The Pennsylvania State University, University Park, Pennsylvania

Ethics, cancer and COVID
Arthur Caplan, NYU Langone Health, New York, New York

Closing Remarks / Discussion
Marina Garassino

Symposium 8: COVID-19 Diagnostics Development
2:20-4:20 p.m.

Introduction
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

When cancer research goes viral
Douglas R. Lowy, National Cancer Institute, Bethesda, Maryland

Highly sensitive and full-genome interrogation of SARS-CoV-2 using multiplexed PCR enrichment followed by next-generation sequencing* 
Chenyu Li, Paragon Genomics, Hayward, California

Title to be announced
Patrick D. Hsu, University of California, Berkeley, California

Rapid isothermal SARS-CoV-2 detection using RT-LAMP 
Brian Rabe, Harvard Medical School, Boston Massachusetts

Closing Remarks / Discussion
David A. Tuveson

Wednesday, July 22, 2020

Symposium 9: Health Inequities and Disparities in the COVID-19 Pandemic
10 a.m.-12 p.m.

Introduction
Clayton C. Yates, Tuskegee University, Tuskegee, Alabama

Potential insights into COVID-19 disparities from the science of cancer health disparities
John M. Carethers, University of Michigan, Ann Arbor, Michigan

Cancer and race: two important risk factors for COVID-19 incidence as captured by the COVID Symptom Study real-time epidemiology tool*
David A. Drew, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts

Outcomes by race for cancer patients hospitalized with SARS-CoV-2 infection*
Steven S. Chang, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan

Factors affecting COVID-19 outcomes in cancer patients: A first report from Guy’s Cancer Centre in London*
Saoirse Dolly, Guy’s and St Thomas’ NHS Foundation Trust and Kings Health Partners, London, England

Unemployment and cancer screening: Baseline estimates to inform healthcare provision in the context of COVID-19 economic distress*
Stacey Fedewa, American Cancer Society, Atlanta, Georgia

Title to be announced
Cheryl L. Willman, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico

Closing Remarks / Discussion
Clayton C. Yates

Symposium 10: Risk Factors and Comorbidities Resulting in Adverse Outcomes for Cancer Patients with COVID-19
10 a.m.-12 p.m.

Introduction
Lucile L. Adams-Campbell, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

Title to be announced
Helen Su, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland

COVID-19 severity and outcomes in hospitalized patients with cancer at a New York City tertiary medical center: A matched cohort study*
Gagandeep Brar, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York

Using Real-World Data (RWD) from an integrated platform for rapid analysis of patients with cancer with and without COVID-19 across distinct health systems*
Shirish M. Gadgeel, Henry Ford Cancer Institute, Detroit, Michigan

Increased risk of COVID-19 related death among cancer survivors*
Jie Shen, Virginia Commonwealth University, Richmond, Virginia

Cancer and Covid-19: Are non-cancer risks the same?
Leora Horwitz, NYU Langone Health, New York, New York

Closing Remarks / Discussion
Lucile L. Adams-Campbell

Forum 5: Public-Private Partnerships Poised to Address COVID-19
12:15-1:15 p.m.
Moderator: E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

Ramy Ibrahim, Parker Institute for Cancer Immunotherapy, San Francisco, California
David R. Kaufman, Bill and Melinda Gates Foundation, Seattle, Washington
Andrew S. Plump, Takeda Pharmaceutical Company, Cambridge, Massachusetts 
Ellen V. Sigal, Friends of Cancer Research, Washington, DC
Tal Z. Zaks, Moderna, Inc., Cambridge, Massachusetts

Forum 6: Health Disparities
12:15-1:15 p.m.
Moderator: John D. Carpten, Keck School of Medicine of USC, Los Angeles, California

Vadim Backman, Northwestern University, Evanston, Illinois
Rea Blakey, U.S. Food and Drug Administration Oncology Center of Excellence, Silver Spring, Maryland
John M. Carethers, University of Michigan, Ann Arbor, Michigan
Kevin Cassel, University of Hawai’i Cancer Center, Honolulu, Hawaii
Lisa A. Newman, Weill Cornell Medicine, New York, New York

Symposium 11: Cancer Prevention and Early Detection during the COVID-19 Pandemic
1:30-3:30 p.m.

Introduction
Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

Title to be announced
Lisa C. Richardson, Centers for Disease Control and Prevention, Atlanta, Georgia

Assessing the impact of the COVID-19 pandemic on cancer patients, survivors and caregivers*
Amy Leader, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

Patient-reported impact of the COVID-19 pandemic on breast cancer screening, diagnosis, and treatment: A national survey*
Erica T. Warner, Massachusetts General Hospital, Boston, Massachusetts

Impact of COVID-19 on breast and prostate cancer screening and early detection in a large healthcare provider group*
Mara M. Epstein, University of Massachusetts Medical School, Worcester, Massachusetts

Title to be announced
Otis W. Brawley, Johns Hopkins University, Baltimore, Maryland

Closing Remarks / Discussion
Karen E. Knudsen

Symposium 12: Epidemiology and Registries of COVID-19 and Cancer
1:30-3:30 p.m.

Introduction
Gypsyamber D’Souza, Johns Hopkins University, Baltimore, Maryland

Understanding the impact of COVID in cancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums
Brian I. Rini, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 

High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia*
Arielle Elkrief, Centre de recherche de l’Université de Montréal, Montreal, QC, Canada

Risk of morbidity and mortality in COVID-19 patients with cancer*
Naomi Alpert, Icahn School of Medicine at Mount Sinai, New York, New York

Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small cell lung cancer and other rare thoracic malignancies*
Alessio Cortellini, University of L’Aquila, L’Aquila, Italy

Title to be announced
Justin Lessler, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Closing Remarks / Discussion
Gypsyamber D’Souza

Break
3:30-3:45 p.m.
Keynote Address
3:45-4:20 p.m.

Introduction
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Keynote Address
Trevor Bedford, Fred Hutchinson Cancer Research Center, Seattle, Washington

Break
4:20-4:35 p.m.
Closing Roundtable Session: Returning to Cancer Research during COVID-19
4:35-6 p.m.
Moderator: Elizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland

Introduction    
Elizabeth M. Jaffee

Title to be announced
Norman E. Sharpless, National Cancer Institute, Bethesda, Maryland

Panel Discussion / Q&A
Elizabeth M. Jaffee
Antoni Ribas, University of California, Los Angeles, California
Norman E. Sharpless
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Closing Remarks
Antoni Ribas
David A. Tuveson

*Short talks from proffered papers